In the United States, around 1 million people are living with multiple sclerosis. Out of these, 80-85% of people diagnosed with multiple sclerosis have relapsing-remitting multiple sclerosis, making it the most common sub-type. Therefore, researchers are emphasizing on developing high-quality and potent drugs to manage the disease effectively.
Major companies involved in the relapsing remitting multiple sclerosis pipeline drugs market include Celgene, Hoffmann-La Roche, Hikma Pharmaceuticals LLC and Biogen.
Leading drugs currently under pipeline include ANK-700, and IMCY-0141 among others.
Regulatory authorities such as the United States FDA and EMA play an essential role in the relapsing remitting multiple sclerosis treatmentfor relapsing remitting multiple sclerosis as they are offering breakthrough designations to manage the condition.
The Relapsing Remitting Multiple Sclerosis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into relapsing remitting multiple sclerosis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for relapsing remitting multiple sclerosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The relapsing remitting multiple sclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from relapsing remitting multiple sclerosis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing relapsing remitting multiple sclerosis product development activities related to relapsing remitting multiple sclerosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Relapsing-remitting multiple sclerosis (RRMS) is a type of multiple sclerosis. Multiple sclerosis is an autoimmune disorder that affects the central nervous system. It causes the immune system to attack the insulation protection on the nerves called myelin, leading to difficulties in passing signals. With relapsing-remitting multiple sclerosis, an individual witnesses flare-ups or remissions. It is the most common type of multiple sclerosis. Most individuals diagnosed with the disease start with RRMS.
There are different treatment alternatives available to treat the diseases. These work by slowing down disease progression and reducing inflammation. The route of administration can be oral, or infusion based.
This section of the report covers the analysis of relapsing remitting multiple sclerosis drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s relapsing remitting multiple sclerosis therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for relapsing remitting multiple sclerosis. There are around 142 drugs in phase II of relapsing remitting multiple sclerosis drugs.
The drug molecule categories covered under relapsing remitting multiple sclerosis pipeline analysis include immunomodulators, oral disease-modifying therapies, monoclonal antibodies, selective adhesion molecule inhibitors and immunosuppressants. The choice of treatment depends on the stage of the disease, patient allergies, and multiple factors.
The EMR report for the relapsing remitting multiple sclerosis drug insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in relapsing remitting multiple sclerosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for spinal fusion. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of spinal fusion drug candidates.
This drug is under investigation for its safety and tolerability against relapsing remitting multiple sclerosis in adults. Sponsored by Anokion SA, the Phase 1 study is divided into 2 arms, wherein the patients in part A receive a single dose of the drug while the patients in part B will either receive 3 doses of ANK-700 or placebo.
Roche is conducting a Phase 3 randomised, double-blind, multicenter study to examine the efficacy and safety of the drug in comparison to finglomod taken orally. Ocrelizumab will be intravenously administered every 24 weeks to children as well as adolescents (aged between 10-18 years) affected with relapsing-remitting multiple sclerosis.
Sponsored by Imcyse SA, this experimental drug is in Phase 1 for treating relapsing-remitting multiple sclerosis. Based on a new mechanism, it is part of an interventional study that has 150 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Relapsing Remitting Multiple Sclerosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for relapsing remitting multiple sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into relapsing remitting multiple sclerosis collaborations, regulatory environments, and potential growth opportunities within relapsing remitting multiple sclerosis pipeline insights.
Upto 30% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share